Award Data

DESCRIPTION (provided by applicant): Lung cancer is the most prevalent cancer worldwide and responsible for the most cancer deaths in the United States. Existing therapies include surgery, radiation, or chemotherapy to kill the tumor cells, but these options are not adequate for the vast majority of patients. Thus, there is a significant need to develop new therapeutic approaches. One of the most ...

DESCRIPTION (provided by applicant): Aminoglycoside antibiotics (AGs) are important for the treatment of a variety of serious infectious diseases including septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. AGs are the mainstay of treating Pseudomonas infection in patients with cystic fibrosis and one of the best c ...

DESCRIPTION (provided by applicant): The goal of this project is to develop a novel peptide therapeutic, GLP-1-5, for the treatment of obesity. Today, one-third of adults in the United States (US) are obese, with an estimated annual healthcare burden of approximately 150 billion. By 2030, it is projected that over 50% of adults in the US will be obese with a yearly healthcare burden expected to e ...

DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to evaluate a novel vascular graft design for use as the arteriovenous (AV) graft component of a new needle-free access port. Significance: Hemodialysis patients require painful punctures with large needles for vascular access on a near-daily basis. This worsens quality of life, and the repeated tissue trauma makes ...

DESCRIPTION (provided by applicant): This SBIR Phase I project will determine the feasibility of using Self-Digitization (SD) microfluidic technology as a commercially competitive nucleic acid quantification (NAQ) platform. Quantification of nucleic acids(both DNA and RNA) is utilized in various fields including general research, biomedical research, and clinical diagnostics, with specific applica ...

? DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project will demonstrate the feasibility of using microbial induced calcite precipitation by indigenous soil bacteria to reduce the mobility of lead in contaminatedsoils and collect metal adapted ureolytic strains from the soil that can potentially be used as exogenous organisms for bioremediations. Lead con ...

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR project is to test the feasibility of using a novel biomaterial design for improved Glaucoma Drainage Device (GDD) performance. The proposed innovation has the eventual aim to enhanceour current STARfloTM Glaucoma Implant device by increasing its drainage efficiency with a fibrosis-minimizing surface geometry. This could allow ...

DESCRIPTION (provided by applicant): In this Phase I project Metheor Therapeutics is proposing a unique approach to developing novel DNA methyltransferase (DNMT) inhibitors, testing the concept of a substrate trap designed to capture and deplete the enzyme. Inhibition of DNMT activity is a validated therapeutic approach for Myelodysplastic Syndrome and Acute Myeloid Leukemia. Two nucleoside analog ...

DESCRIPTION (provided by applicant): Fluorescence based techniques play an essential role in modern cell biology and biomedical research. Further development of these techniques has been hindered by the lack of suitable fluorescent probes. To overcome thischallenge, various fluorescent nanoparticles have been developed. Among those, conjugated polymer dots (Pdots) exhibited superior properties suc ...